Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Modeling of a hyper-inflammatory hematopoietic niche ex vivo reveals a multi-step process driving CAR T- cell associated myeloid leukemia in multiple myeloma

Blood (2025) 146 (Supplement 1): 2152.

https://doi.org/10.1182/blood-2025-2152

Published: 2025

Journal Articles

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and adverse outcome of CAR-T therapy

Blood (2025) 146 (Supplement 1): 809.

https://doi.org/10.1182/blood-2025-809

Published: 2025

Journal Articles

Increased teclistamab dosing interval improves T-cell diversity and reduces infection risk, while T-cell exhaustion remains minimal irrespective of schedule

Blood (2025) 146 (Supplement 1): 802.

https://doi.org/10.1182/blood-2025-802

Published: 2025

Journal Articles

Upregulation of BCMA expression by selinexor

Christina Verbruggen, Umair Munawar, Seungbin Han, Julia Mersi, Emma Besant, Shilpa Kurian, Silvia Nerreter, Nina Rein, Johanna Lehmann, Max Koeppel, Hermann Einsele, Leo Rasche, Johannes Waldschmidt, K. Martin Kortüm

Blood (2025) 146 (Supplement 1): 6102.

https://doi.org/10.1182/blood-2025-6102

Published: 2025

Journal Articles

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

Blood (2025) 146 (Supplement 1): 5785.

https://doi.org/10.1182/blood-2025-5785

Published: 2025

Journal Articles

Elevated NQO1 expression mediates proteasome inhibitor resistance and predicts adverse outcomes in multiple myeloma

Blood (2025) 146 (Supplement 1): 6812.

https://doi.org/10.1182/blood-2025-6812

Published: 2025

Journal Articles

Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials

Rakesh Popat, Katarina Uttervall, Aurore Perrot, Hila Magen, Vitaliy Mykytiv, Carmine Liberatore, Elena Zamagni, Matteo Claudio Da Vià, Elisabetta Antonioli, Markus Hansson, Danielle Greer, Peter Hu, Eric Aeby, Krystof Subrt, Nicholas Francella, Diptendu Santra, Natalia Martin Suñe, K. Martin Kortüm

Blood (2025) 146 (Supplement 1): 4573.

https://doi.org/10.1182/blood-2025-4573

Published: 2025

Journal Articles

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Blood (2025) 146 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2025-2178

Published: 2025

Journal Articles

Impact of bortezomib on T-cell subsets and immune checkpoints under bispecific antibody therapy in multiple myeloma

Xiang Zhou, Umair Munawar, Shilpa Kurian, Seungbin Han, Mara John, Hanna Fischer, Silvia Nerreter, Lenka Besse, Andrej Besse, Christoph Driessen, Marc Schmalzing, Johannes Waldschmidt, Hermann Einsele, Leo Rasche, K. Martin Kortüm

Blood (2025) 146 (Supplement 1): 2174.

https://doi.org/10.1182/blood-2025-2174

Published: 2025

Journal Articles

Novel insights in therapeutic antibody therapies using advanced microscopy techniques

Christina Verbruggen, Patrick Eiring, Max Steinhardt, Julia Weingart, Umair Munawar, Seungbin Han, Sven Neubert, Emma Besant, Cornelia Vogt, Silvia Nerreter, Shilpa Kurian, Nina Rein, Johanna Lehmann, Max Koeppel, Hermann Einsele, Johannes Waldschmidt, Markus Sauer, K. Martin Kortüm

Blood (2025) 146 (Supplement 1): 6111.

https://doi.org/10.1182/blood-2025-6111

Published: 2025

Journal Articles

Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma

Blood (2025) 146 (Supplement 1): 7465.

https://doi.org/10.1182/blood-2025-7465

Published: 2025

Journal Articles

TeclistAMY (EMN40): A Phase 2 trial of teclistamab in patients with previously treated light-chain (AL) amyloidosis

Murielle Roussel, Efstathios Kastritis, Stefan Schönland, K. Martin Kortüm, Bertrand Arnulf, Arnaud Jaccard, Sanjay Vara, Margaret Doyle, Jordan Schecter, Alexander Carpinteiro, Fiona Kwok, Giovanni Palladini, Monique Minnema, Mario Boccadoro, Pieter Sonneveld

Blood (2025) 146 (Supplement 1): 3974.

https://doi.org/10.1182/blood-2025-3974

Published: 2025

Journal Articles

Clinical, anatomic, and histologic determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis: A cohort study of 560 patients

Blood (2025) 146 (Supplement 1): 3962.

https://doi.org/10.1182/blood-2025-3962

Published: 2025

Journal Articles

Single-cell profiling reveals teclistamab-induced reshaping of nasopharyngeal immunity in multiple myeloma

Sofie-Katrin Kadel, Alexander Leipold, Philipp Weis, Tobias Krammer, Lukas Scheller, Julia Mersi, Nazia Afrin, Johannes Waldschmidt, K. Martin Kortüm, Hermann Einsele, Antoine-Emmanuel Saliba, Leo Rasche

Blood (2025) 146 (Supplement 1): 5698.

https://doi.org/10.1182/blood-2025-5698

Published: 2025

Journal Articles

NQO1 modulates CD38 surface expression in multiple myeloma

Seungbin Han, Christina Verbruggen, Silvia Nerreter, Umair Munawar, Shilpa Kurian, Emma Besant, Ann-Sophie Hainold, Cornelia Vogt, Xiang Zhou, Hermann Einsele, Leo Rasche, Markus Sauer, Johannes Waldschmidt, K. Martin Kortüm

Blood (2025) 146 (Supplement 1): 5718.

https://doi.org/10.1182/blood-2025-5718

Published: 2025

Journal Articles

Talquetamab alters T cell transcriptome in presence of GPRC5D on MM cells

Umair Munawar, Alexander Leipold, Silvia Nerreter, Seungbin Han, Shilpa Kurian, Emma Besant, Nina Rein, Max Koeppel, Johanna Lehmann, Xiang Zhou, Hermann Einsele, Leo Rasche, Emmanuel Saliba, Johannes Waldschmidt, K. Martin Kortüm

Blood (2025) 146 (Supplement 1): 5701.

https://doi.org/10.1182/blood-2025-5701

Published: 2025

Journal Articles

Lattice light-sheet microscopy reveals patient specific responses to CD20-directed antibodies in B cell malignancies

Julia Weingart, Patrick Eiring, Umair Munawar, Seungbin Han, Christina Verbruggen, Silvia Nerreter, Shilpa Kurian, Max Steinhardt, Leo Rasche, Hermann Einsele, Johannes Waldschmidt, K. Martin Kortüm, Markus Sauer

Blood (2025) 146 (Supplement 1): 4343.

https://doi.org/10.1182/blood-2025-4343

Published: 2025

Journal Articles

An acquired immune-metabolic shift to common chemotherapy confers resistance to immunotherapies in relapsed, high-risk multiple myeloma

Blood (2025) 146 (Supplement 1): 3938.

https://doi.org/10.1182/blood-2025-3938

Published: 2025

Journal Articles

Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens

Blood blood.2024027616.

https://doi.org/10.1182/blood.2024027616

Published: 2025

Includes: Supplemental data

Journal Articles

Guidance on the interpretation of CRBN mutations in myeloma

K. Martin Kortüm, Hermann Einsele

Blood (2025) 145 (22): 2542.

https://doi.org/10.1182/blood.2024028272

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Modeling of a hyper-inflammatory hematopoietic niche ex vivo reveals a multi-step process driving CAR T- cell associated myeloid leukemia in multiple myeloma

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and adverse outcome of CAR-T therapy

Increased teclistamab dosing interval improves T-cell diversity and reduces infection risk, while T-cell exhaustion remains minimal irrespective of schedule

Upregulation of BCMA expression by selinexor

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

Elevated NQO1 expression mediates proteasome inhibitor resistance and predicts adverse outcomes in multiple myeloma

Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Impact of bortezomib on T-cell subsets and immune checkpoints under bispecific antibody therapy in multiple myeloma

Novel insights in therapeutic antibody therapies using advanced microscopy techniques

Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma

TeclistAMY (EMN40): A Phase 2 trial of teclistamab in patients with previously treated light-chain (AL) amyloidosis

Clinical, anatomic, and histologic determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis: A cohort study of 560 patients

Single-cell profiling reveals teclistamab-induced reshaping of nasopharyngeal immunity in multiple myeloma

NQO1 modulates CD38 surface expression in multiple myeloma

Talquetamab alters T cell transcriptome in presence of GPRC5D on MM cells

Lattice light-sheet microscopy reveals patient specific responses to CD20-directed antibodies in B cell malignancies

An acquired immune-metabolic shift to common chemotherapy confers resistance to immunotherapies in relapsed, high-risk multiple myeloma

Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens

Guidance on the interpretation of CRBN mutations in myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only